A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study.
about
Pharmacotherapies for obesity: past, current, and future therapiesCannabinoid type 1 receptor antagonists for smoking cessationAnti-Obesity Drugs: A Review about Their Effects and SafetyEndocannabinoid-mediated synaptic plasticity and addiction-related behaviorNew and emerging drug molecules against obesity.Neuroendocrine circuits governing energy balance and stress regulation: functional overlap and therapeutic implicationsRimonabant improves metabolic parameters partially attributed to restoration of high voltage-activated Ca2+ channels in skeletal muscle in HFD-fed miceSurinabant, a selective cannabinoid receptor type 1 antagonist, inhibits Δ9-tetrahydrocannabinol-induced central nervous system and heart rate effects in humansCombination of very low energy diets and pharmacotherapy in the treatment of obesity: meta-analysis of published data.Association of genetic variation in cannabinoid mechanisms and gastric motor functions and satiation in overweight and obesity.Current pharmacotherapy for obesity: extrapolation of clinical trials data to practice.Endocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors.A PET study comparing receptor occupancy by five selective cannabinoid 1 receptor antagonists in non-human primates.Cannabinoid discrimination and antagonism by CB(1) neutral and inverse agonist antagonists.Comparative efficiency and safety of pharmacological approaches to the management of obesity.Stimulants for the Control of Hedonic Appetite.Does the Gut Microbiota Contribute to Obesity? Going beyond the Gut Feeling.Central nervous system biomarkers for antiobesity drug developmentRimonabant redux and strategies to improve the future outlook of CB1 receptor neutral-antagonist/inverse-agonist therapies.Cannabinoid-1 receptor (CB1R) blockers as medicines: beyond obesity and cardiometabolic disorders to substance abuse/drug addiction with CB1R neutral antagonists.Recent advances in the pathophysiology and pharmacological treatment of obesity.Limitations in anti-obesity drug development: the critical role of hunger-promoting neurons.Do we need anti-obesity drugs?Drug-target residence time--a case for G protein-coupled receptors.Translational Modeling to Guide Study Design and Dose Choice in Obesity Exemplified by AZD1979, a Melanin-concentrating Hormone Receptor 1 Antagonist.Evolution of pharmacological obesity treatments: focus on adverse side-effect profiles.Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trials.Characterization of a novel, brain-penetrating CB1 receptor inverse agonist: metabolic profile in diet-induced obese models and aspects of central activity.Low brain CB1 receptor occupancy by a second generation CB1 receptor antagonist TM38837 in comparison with rimonabant in nonhuman primates: a PET study.Cannabinoid 1 G protein-coupled receptor (periphero-)neutral antagonists: emerging therapeutics for treating obesity-driven metabolic disease and reducing cardiovascular risk.The Endocannabinoid System and Heart Disease: The Role of Cannabinoid Receptor Type 2.The cannabinoid-1 receptor inverse agonist taranabant reduces abdominal pain and increases intestinal transit in mice.
P2860
Q21296814-372F9951-CA46-4BBE-A804-B59FD7BFE68AQ24235611-0ADA9D7A-BA79-4B29-AA4D-CE65D9157976Q24630947-7D8A10E4-6719-4854-996B-E68A12C9568CQ29042501-D8E678B5-5C74-41B2-8F7E-28BAA1B7530AQ30353872-C6A99264-A366-4EFB-A0FF-22B3F012D7C4Q33717424-D80D0A79-995E-4988-A8D3-F7E4265D87E3Q33718134-8AFBC8B7-AD45-40C8-8B81-859129976201Q34320289-E7E6EA9A-9730-453B-9BA9-B01CDE7BF786Q35014095-A4A99688-B401-44D3-81B5-B34B206B8FDFQ35053292-F0A8930F-DA18-4506-87FD-4105F30FC306Q35096627-52729E31-129C-4114-9878-A6C34E3418B7Q35532072-56BA3E7A-736B-43DA-BED3-F25115B10343Q36368922-2F458B53-0015-412C-8DD8-B3856C24AE0FQ36642428-62EB5660-21F3-4706-9E47-77D7FB520802Q36783891-6A6CB0C3-205D-489E-941A-029480F3DFBBQ36830567-A9AE9682-2C45-40A9-8A93-6C120EB5AF4EQ37255922-0E9FD319-BF30-4776-97B3-7A967D2284C7Q37382285-E5C0B53A-3F80-44BB-9CE5-7F091BC0058EQ37862977-9E6849D4-A617-4716-B85E-BEFF4A0CA99FQ37984087-92E4BCF7-FD12-4E9E-80FE-EB61833F5B75Q37998514-EA225E31-43C9-4564-94E3-2B4163377757Q38031743-A44B3315-CCDA-447A-8464-0A0DB07954FEQ38071006-10332465-A37C-4905-9652-8C8230F13F28Q38189272-D2147ADF-D5B7-41D6-86A5-B55A1BB0D4A6Q38757203-099CDC79-6002-44A5-B3A9-AA9ACA109426Q38758765-F7DD316B-C2FA-4C71-805E-B19C3B10F76DQ38848626-DAE5346D-575B-40AD-AB20-86B9A846C9B0Q43432897-97859E55-10DE-4CC0-83FC-D2389FF9C6A6Q44010230-A76B6662-FC7D-4170-A385-2A479A78B6EFQ45288843-33614082-7CE3-4B9C-A71C-9A7212B13F57Q50142905-27CCFE8D-24BF-4D8E-91D5-B88F1969FF64Q50975152-A0A6BA3C-7B8C-4398-9096-B776C0E9603D
P2860
A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study.
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
A clinical trial assessing the ...... t patients: a high-dose study.
@ast
A clinical trial assessing the ...... t patients: a high-dose study.
@en
A clinical trial assessing the ...... t patients: a high-dose study.
@nl
type
label
A clinical trial assessing the ...... t patients: a high-dose study.
@ast
A clinical trial assessing the ...... t patients: a high-dose study.
@en
A clinical trial assessing the ...... t patients: a high-dose study.
@nl
prefLabel
A clinical trial assessing the ...... t patients: a high-dose study.
@ast
A clinical trial assessing the ...... t patients: a high-dose study.
@en
A clinical trial assessing the ...... t patients: a high-dose study.
@nl
P2093
P2860
P356
P1476
A clinical trial assessing the ...... t patients: a high-dose study.
@en
P2093
A G Meehan
J M Amatruda
K D Kaufman
L J Aronne
P2860
P2888
P304
P356
10.1038/IJO.2010.21
P407
P577
2010-02-16T00:00:00Z
P5875
P6179
1018368508